Financial Data and Key Metrics Changes - The company achieved record annual worldwide revenue of nearly $201 million, marking over 20% growth year-over-year [5][21] - Fourth quarter worldwide revenue grew 15% to a record $56.3 million, with U.S. revenue at $53.5 million, representing 13.9% growth [20] - Positive Adjusted EBITDA of $5.1 million in the fourth quarter, a 176.2% improvement over the prior year, with a 9.1% Adjusted EBITDA margin [23][24] - Net loss narrowed to $1.6 million or $0.04 per diluted share in the fourth quarter, compared to a net loss of $4.5 million or $0.11 per diluted share last year [22] Business Line Data and Key Metrics Changes - The company reported a 22% increase in U.S. physicians using its technologies, with nearly 22,000 procedures performed in 2025 [6][20] - INTRA Ti was launched recently, expected to enhance procedural efficiency in SI joint fusion [9][10] - iFuse Bedrock Granite has been one of the fastest-growing platforms, significantly outpacing the overall deformity market growth rate [11] Market Data and Key Metrics Changes - International revenue in the fourth quarter was $2.9 million, growing 38.8%, driven by the reception of iFuse TORQ [20] - The company secured favorable reimbursement positions, including NTAP for iFuse TORQ TNT and TPT for iFuse Bedrock Granite, enhancing access and adoption [6][11] Company Strategy and Development Direction - The company aims to lead the market for patients with compromised bone, focusing on innovation and market development [8] - A strategic partnership with Smith+Nephew was announced to expand reach in the trauma market, allowing trauma surgeons access to breakthrough technologies [16][29] - The next five years are viewed as an innovation super cycle, with plans to launch unique technologies targeting new clinical adjacencies [7][55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in long-term growth potential, supported by a robust pipeline of innovative products and expanding market opportunities [28] - The company expects worldwide revenue of $228.5 million to $232.5 million in 2026, implying year-over-year growth of 14%-16% [25][26] - Management highlighted the importance of allowing tailwinds to materialize before fully incorporating them into revenue expectations [52][83] Other Important Information - The company exited 2025 with $147.8 million in cash and equivalents, marking a significant improvement in cash consumption compared to the previous year [24] - The company plans to add 10 new territories in 2026 to capture market opportunities [16][66] Q&A Session Summary Question: On the Smith+Nephew partnership, how did it come about and its potential contribution? - Management expressed excitement about the partnership, highlighting its potential to expand access to trauma solutions and allow the sales force to focus on market development [29][30] Question: Regarding clinical data showing similar outcomes for IPM physicians, will this increase engagement? - Management noted the growing interest in interventional business and the launch of INTRA Ti, which aligns with interventional spine physicians' workflows [32][34] Question: Can you clarify the guidance for Adjusted EBITDA in 2026? - Management indicated that while they expect an increase in Adjusted EBITDA, it would be slightly below $20 million [44] Question: What is the expected impact of INTRA Ti on the ASC market? - Management highlighted that INTRA Ti is designed for the ASC market and is expected to drive additional sales due to its simplicity and reimbursement coverage [46][62] Question: Can you discuss the cadence of revenue and the expected tailwinds? - Management noted that they expect more tailwinds than ever before, with a strong physician base and improved reimbursement backdrop [52][53]

Financial Data and Key Metrics Changes - The company generated record annual worldwide revenue of nearly $201 million, marking over 20% growth year-over-year [5][20] - Fourth quarter worldwide revenue grew 15% to a record $56.3 million, with U.S. revenue at $53.5 million, representing 13.9% growth [19][20] - The company achieved its first full year of positive Adjusted EBITDA, with a margin of 9% in the fourth quarter [6][23] - Net loss narrowed to $1.6 million or $0.04 per diluted share in the fourth quarter, compared to a net loss of $4.5 million or $0.11 per diluted share last year [22][23] - The company exited 2025 with $147.8 million in cash and equivalents, an increase of $2.1 million from the third quarter [24] Business Line Data and Key Metrics Changes - The U.S. physician base grew by 22%, with over 2,400 physicians performing nearly 22,000 procedures in 2025 [5][20] - The company launched the INTRA Ti product, which is expected to enhance procedural efficiency in ambulatory surgery centers [9][10] - iFuse Bedrock Granite has been one of the fastest-growing platforms, significantly outpacing the overall deformity market growth rate [11] Market Data and Key Metrics Changes - International revenue in the fourth quarter was $2.9 million, growing 38.8%, driven by the reception of iFuse TORQ [19][20] - The company secured favorable reimbursement positions, including NTAP for iFuse TORQ TNT and TPT for iFuse Bedrock Granite, enhancing access and adoption [5][11] Company Strategy and Development Direction - The company aims to lead the sacroiliac joint fusion market and expand into new clinical adjacencies, targeting unmet needs for patients with compromised bone [6][8] - The partnership with Smith+Nephew is expected to enhance market penetration in trauma solutions [16][30] - The company anticipates an innovation super cycle over the next five years, with regular product launches targeting new clinical adjacencies [7][57] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of the business, supported by a robust pipeline of innovative products and expanding market opportunities [27] - The company expects worldwide revenue of $228.5 million to $232.5 million in 2026, implying year-over-year growth of 14%-16% [25][26] - Management highlighted the importance of allowing tailwinds to materialize before fully incorporating them into revenue expectations [54][86] Other Important Information - The company achieved positive free cash flow in the fourth quarter, generating nearly $500,000, ahead of its previously stated goal [24] - The company plans to add 10 new territories in 2026 to capture market opportunities [16][69] Q&A Session Summary Question: How did the Smith+Nephew partnership come about and its potential contribution? - Management expressed excitement about the partnership, highlighting its potential to expand access to trauma solutions and allow the sales force to focus on spine and interventional markets [30][32] Question: Will the INTRA Ti product create more engagement among interventional physicians? - Management confirmed that the INTRA Ti product is designed to improve procedural efficiency and is expected to drive growth in the interventional business [34][49] Question: What is the rationale behind the high teens growth guidance for 2026? - Management explained that the guidance considers the impact of new products and reimbursement coverage, with a focus on prudent expectations early in the year [86] Question: What is the expected ramp-up for the Smith+Nephew partnership in 2026? - Management indicated that activity is expected to start in March, with a ramp-up in Q2 and Q3 in preparation for Q4 [74][75]

Core Viewpoint - The article discusses the challenges faced by Medtronic, including stagnation in growth, innovation fatigue, and pressure from activist investors, while exploring the potential for restructuring or revitalization [2][4]. Group 1: Activist Investor Involvement - Elliott Investment Management has entered Medtronic's shareholder list, advocating for a reassessment of the business portfolio and a focus on core assets to enhance shareholder returns [6][7]. - The entry of Elliott reflects a broader trend where undervalued large companies are pressured to divest non-core assets and improve capital efficiency [7][8]. - Medtronic's valuation disadvantage compared to peers indicates investor concerns regarding its management structure and innovation efficiency [8][9]. Group 2: Growth and Innovation Challenges - Medtronic's issues are traced back to the 2015 acquisition of Covidien, which has led to integration difficulties and cultural clashes [10][11]. - Financially, Medtronic reported approximately $32.3 billion in revenue for FY2024, with a net profit of about $5.1 billion, but its growth rate of 3% is below industry peers [11][12]. - The company's R&D spending of $2.6 billion represents only 8.1% of revenue, lower than competitors, indicating a slowdown in innovation output [14][15]. Group 3: Investor Perspective - Investors view Medtronic as a "sleeping giant," with stable financials but lacking growth appeal, as evidenced by a total shareholder return of less than 4% over the past five years [15][16]. - There is a demand for not just cost optimization but also significant innovation to change the valuation narrative [16][19]. Group 4: CEO's Response - CEO Geoff Martha asserts that Medtronic is in an "Innovation Super Cycle," with significant new products expected to launch between 2025 and 2027 [16][20]. - Martha emphasizes that the company's focus is on portfolio reshaping to enhance innovation rather than breaking up the company [19][20]. - The management is undergoing a dual reboot of structure and personnel to improve decision-making speed and execution [22][23]. Group 5: Future Directions - Medtronic aims to focus on financial recovery through divesting low-margin businesses and simplifying its organizational structure [23][24]. - The company is also working on bringing high-tech platforms to market, although the timeline for significant sales remains extended [24][25]. - The shift in focus from expansion to innovation reflects a recalibration towards core technological strengths, with the challenge of balancing innovation delivery and capital returns [25].